PL374963A1 - Sposób chemiczny - Google Patents
Sposób chemicznyInfo
- Publication number
- PL374963A1 PL374963A1 PL03374963A PL37496303A PL374963A1 PL 374963 A1 PL374963 A1 PL 374963A1 PL 03374963 A PL03374963 A PL 03374963A PL 37496303 A PL37496303 A PL 37496303A PL 374963 A1 PL374963 A1 PL 374963A1
- Authority
- PL
- Poland
- Prior art keywords
- chemical process
- chemical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38934902P | 2002-06-17 | 2002-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PL374963A1 true PL374963A1 (pl) | 2005-11-14 |
Family
ID=29736629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL03374963A PL374963A1 (pl) | 2002-06-17 | 2003-06-17 | Sposób chemiczny |
Country Status (10)
Country | Link |
---|---|
US (1) | US20060252943A1 (pl) |
EP (1) | EP1515955A4 (pl) |
JP (1) | JP2005529954A (pl) |
CN (1) | CN1688553A (pl) |
AU (1) | AU2003276125B2 (pl) |
CA (1) | CA2489648A1 (pl) |
IL (1) | IL165286A0 (pl) |
MX (1) | MXPA04012860A (pl) |
PL (1) | PL374963A1 (pl) |
WO (1) | WO2003106416A2 (pl) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
CN103169708B (zh) | 2002-07-29 | 2018-02-02 | 里格尔药品股份有限公司 | 用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法 |
EP1608317B1 (en) | 2003-03-25 | 2012-09-26 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
RS53109B (en) | 2003-07-30 | 2014-06-30 | Rigel Pharmaceuticals Inc. | 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES |
US7579357B2 (en) | 2003-08-13 | 2009-08-25 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1659155B1 (en) | 2003-08-25 | 2016-11-16 | Kaneka Corporation | Curing composition with improved heat resistance |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
CN102127057A (zh) | 2004-03-15 | 2011-07-20 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
WO2006020564A1 (en) * | 2004-08-09 | 2006-02-23 | Smithkline Beecham Corporation | Pyrimidin derivatives for the treatment of multiple myeloma |
JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
ES2337496T3 (es) | 2005-01-19 | 2010-04-26 | Rigel Pharmaceuticals, Inc. | Profarmacos de compuestos de 2,4-pirimidindiamina y sus usos. |
US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
NZ563454A (en) | 2005-06-08 | 2011-03-31 | Rigel Pharmaceuticals Inc | 2,4-diaminopyrimidine derivatives for inhibition of the JAK pathway |
ZA200802857B (en) | 2005-09-14 | 2009-09-30 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
WO2007064753A2 (en) | 2005-11-29 | 2007-06-07 | Smithkline Beecham Corporation | Cancer treatment method |
AU2006320535B2 (en) * | 2005-11-29 | 2010-09-23 | Glaxosmithkline Llc | Treatment method |
EP1991532B1 (en) | 2006-02-24 | 2017-01-11 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
DK2154967T5 (en) | 2007-04-16 | 2014-11-17 | Hutchison Medipharma Entpr Ltd | Pyriminderivater |
ES2546502T3 (es) | 2008-04-16 | 2015-09-24 | Portola Pharmaceuticals, Inc. | 2,6-Diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o JAK quinasas |
SG2014015085A (en) | 2008-04-16 | 2014-06-27 | Portola Pharm Inc | 2,6-diamino-pyrimidin-5-yl-carboxamides as syk or jak kinases inhibitors |
US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
JP2011518219A (ja) | 2008-04-22 | 2011-06-23 | ポートラ ファーマシューティカルズ, インコーポレイテッド | タンパク質キナーゼの阻害剤 |
US20120232102A1 (en) | 2009-09-30 | 2012-09-13 | Chun-Fang Xu | Methods Of Administration And Treatment |
EP2490536A4 (en) * | 2009-10-23 | 2013-04-17 | Glaxo Wellcome Mfg Pte Ltd | COMPOSITION AND METHOD |
WO2011058179A1 (en) | 2009-11-16 | 2011-05-19 | Ratiopharm Gmbh | 5- (4- (n- (2, 3 -dimethyl- 2h- indazol- 6 -yl) -n-methylamino) pyrimidin- 2 -ylamino) -2 -methylbenzenesulfonamide |
WO2011069053A1 (en) | 2009-12-04 | 2011-06-09 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of pazopanip hcl and crystalline forms of pazopanib hcl |
US8846928B2 (en) | 2010-11-01 | 2014-09-30 | Portola Pharmaceuticals, Inc. | Benzamides and nicotinamides as Syk modulators |
EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
WO2012061415A1 (en) | 2010-11-01 | 2012-05-10 | Portola Pharmaceuticals, Inc. | Oxypyrimidines as syk modulators |
EP2646431B1 (en) * | 2010-11-29 | 2016-04-06 | Hetero Research Foundation | A process for the preparation of pazopanib using novel intermediate |
CN102060848B (zh) * | 2010-12-09 | 2013-09-18 | 天津药物研究院 | 芳香胺取代的嘧啶衍生物的制备及用途 |
US9359308B2 (en) | 2011-11-23 | 2016-06-07 | Portola Pharmaceuticals, Inc. | Pyrazine kinase inhibitors |
CN103319410B (zh) * | 2012-03-22 | 2016-04-06 | 天津药物研究院 | 一种吲唑化合物的合成方法 |
CN103373963B (zh) * | 2012-04-28 | 2015-07-08 | 上海医药工业研究院 | 盐酸帕唑帕尼的中间体及其制备方法 |
CN103373989B (zh) * | 2012-04-28 | 2016-04-13 | 上海医药工业研究院 | 盐酸帕唑帕尼的中间体的制备方法 |
WO2014058921A2 (en) | 2012-10-08 | 2014-04-17 | Portola Pharmaceuticals, Inc. | Substituted pyrimidinyl kinase inhibitors |
US9802923B2 (en) | 2012-12-17 | 2017-10-31 | Sun Pharmaceutical Industries Limited | Process for the preparation of pazopanib or salts thereof |
WO2014097152A1 (en) * | 2012-12-17 | 2014-06-26 | Ranbaxy Laboratories Limited | Process for the preparation of pazopanib or salts thereof |
CN103232443B (zh) * | 2013-02-01 | 2014-12-10 | 天津药物研究院 | 一种吲唑衍生物的晶型及其制备和用途 |
CN103450085B (zh) * | 2013-08-15 | 2015-11-18 | 凯莱英医药集团(天津)股份有限公司 | 一种盐酸帕唑帕尼关键中间体的制备方法 |
WO2015068175A2 (en) | 2013-11-05 | 2015-05-14 | Laurus Labs Private Limited | An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof |
CN106565688B (zh) * | 2016-11-11 | 2018-08-31 | 重庆医科大学 | 帕唑帕尼二聚体及其制备方法和用途 |
CN110028495B (zh) * | 2019-05-24 | 2019-12-03 | 济南爱思医药科技有限公司 | 帕唑帕尼盐酸盐的制备方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
WO2001025220A1 (en) * | 1999-10-07 | 2001-04-12 | Amgen Inc. | Triazine kinase inhibitors |
HUP0301117A3 (en) * | 2000-02-17 | 2004-01-28 | Amgen Inc Thousand Oaks | Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them |
JP3711443B2 (ja) * | 2000-10-25 | 2005-11-02 | セイコーエプソン株式会社 | インクジェット式記録装置 |
NZ526542A (en) * | 2000-12-21 | 2005-01-28 | Glaxo Group Ltd | Pyrimidineamines as angiogenesis modulators |
TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
-
2003
- 2003-06-17 MX MXPA04012860A patent/MXPA04012860A/es unknown
- 2003-06-17 WO PCT/US2003/019211 patent/WO2003106416A2/en active IP Right Grant
- 2003-06-17 EP EP03742050A patent/EP1515955A4/en not_active Withdrawn
- 2003-06-17 CA CA002489648A patent/CA2489648A1/en not_active Abandoned
- 2003-06-17 US US10/518,349 patent/US20060252943A1/en not_active Abandoned
- 2003-06-17 IL IL16528603A patent/IL165286A0/xx unknown
- 2003-06-17 JP JP2004513249A patent/JP2005529954A/ja active Pending
- 2003-06-17 CN CNA038141698A patent/CN1688553A/zh active Pending
- 2003-06-17 AU AU2003276125A patent/AU2003276125B2/en not_active Ceased
- 2003-06-17 PL PL03374963A patent/PL374963A1/pl not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2003276125B2 (en) | 2007-05-17 |
CA2489648A1 (en) | 2003-12-24 |
MXPA04012860A (es) | 2005-09-20 |
WO2003106416A3 (en) | 2004-05-06 |
EP1515955A2 (en) | 2005-03-23 |
AU2003276125A1 (en) | 2003-12-31 |
IL165286A0 (en) | 2005-12-18 |
WO2003106416A2 (en) | 2003-12-24 |
CN1688553A (zh) | 2005-10-26 |
JP2005529954A (ja) | 2005-10-06 |
EP1515955A4 (en) | 2006-05-03 |
US20060252943A1 (en) | 2006-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI316058B (en) | Chemical process | |
IL165286A0 (en) | Chemical process | |
GB0324791D0 (en) | Chemical process | |
GB0312896D0 (en) | Chemical process | |
GB0205016D0 (en) | Process | |
GB0320793D0 (en) | Chemical process | |
GB0201505D0 (en) | Process | |
GB0204607D0 (en) | Process | |
GB0218041D0 (en) | Chemical process | |
GB0202564D0 (en) | Process | |
GB0205014D0 (en) | Process | |
GB0229803D0 (en) | Chemical process | |
GB0216412D0 (en) | Chemical process | |
GB0201378D0 (en) | Process | |
GB0210370D0 (en) | Chemical process | |
GB0202563D0 (en) | Process | |
GB0222833D0 (en) | Chemical process | |
GB0203665D0 (en) | Process | |
GB0313920D0 (en) | Chemical process | |
GB0302648D0 (en) | Chemical process | |
GB0221243D0 (en) | Chemical process | |
GB0219829D0 (en) | Process | |
GB0313908D0 (en) | Chemical process | |
GB0313909D0 (en) | Chemical process | |
GB0313910D0 (en) | Chemical process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |